Anesthesia Risk and the Mucopolysaccharidoses: A Challenging and Changing Landscape

Abstract

The mucopolysaccharidoses (MPS) are well known to present a high risk of anesthesia. Predominantly, this risk is not only related to upper airway issues but also to multilevel airway obstruction, respiratory morbidity, and cardiac issues. Before disease-specific treatment became available, the management of the untreated patients with MPS was regarded as the worst airway problem in pediatric anesthetic practice. The last 20 to 30 years have seen great advances in the treatment of the different types of MPS with hematopoietic stem cell transplantation (HSCT) being offered to children with MPS I Hurler sundrome since the 1980s, and more recently enzyme replacement therapy (ERT) becoming available for many MPS subtypes.

These treatments have undoubtedly affected the relative risk involved with an anesthetic. HSCT improves markedly the upper airway and cardiac myocardial function and there is evidence that airway management is much more straightforward. ERT, on the other hand, improves obstructive sleep apnea and exercise tolerance, but the overall effect on the risk of anesthesia is less obvious and airway complications during anesthesia remain at a high level. The impact of improved anesthetic management in the same time frame is borne out by a reduced failed intubation rate in the literature.

The management of the MPS patients necessitates a multidisciplinary approach presently widely practiced in pediatric centers, but successful modes of therapy increasing their life span have pushed many of the extreme anesthetic challenges into adult practice where most anesthetists will be unfamiliar with the problem. This is a problem that needs to be addressed, and solutions to this issue could be collaborative working between pediatric and adult practitioners or an international network of experts available for advice.

Keywords

anesthesia - mucopolysaccharidosis - airway management

• References

• 1 Smith RM. Anesthesia for Infants and Children. 4th ed. St. Louis, MO: CV Mosby; 1980: 533-536
• 2 DeLange C, Gerlings PG, DeKleyn A, Lettinga TW. Some remarks on gargoylism. Acta Paediatr 1943; 31: 398-410
• 3 Hopkins R, Watson JA, Jones JH, Walker M. Two cases of Hunter's syndrome--the anaesthetic and operative difficulties in oral surgery. Br J Oral Surg 1973; 10 (03) 286-299
• 4 Herrick IA, Rhine EJ. The mucopolysaccharidoses and anaesthesia: a report of clinical experience. Can J Anaesth 1988; 35 (01) 67-73
• 5 Kempthorne PM, Brown TCK. Anaesthesia and the mucopolysaccharidoses: a survey of techniques and problems. Anaesth Intensive Care 1983; 11 (03) 203-207
• 6 Sjøgren P, Pedersen T, Steinmetz H. Mucopolysaccharidoses and anaesthetic risks. Acta Anaesthesiol Scand 1987; 31 (03) 214-218
• 7 Baines D, Keneally J. Anaesthetic implications of the mucopolysaccharidoses: a fifteen-year experience in a children's hospital. Anaesth Intensive Care 1983; 11 (03) 198-202
• 8 Belani KG, Krivit W, Carpenter BL. , et al. Children with mucopolysaccharidosis: perioperative care, morbidity, mortality, and new findings. J Pediatr Surg 1993; 28 (03) 403-408 , discussion 408–410
• 9 Walker RW, Darowski M, Morris P, Wraith JE. Anaesthesia and mucopolysaccharidoses. A review of airway problems in children. Anaesthesia 1994; 49 (12) 1078-1084
• 10 Moores C, Rogers JG, McKenzie IM, Brown TC. Anaesthesia for children with mucopolysaccharidoses. Anaesth Intensive Care 1996; 24 (04) 459-463
• 11 Arn P, Whitley C, Wraith JE. , et al. High rate of postoperative mortality in patients with mucopolysaccharidosis I: findings from the MPS I Registry. J Pediatr Surg 2012; 47 (03) 477-484
• 12 Fecho K, Lunney AT, Boysen PG, Rock P, Norfleet EA. Postoperative mortality after inpatient surgery: incidence and risk factors. Ther Clin Risk Manag 2008; 4 (04) 681-688
• 13 Walker R, Belani KG, Braunlin EA. , et al. Anaesthesia and airway management in mucopolysaccharidosis. J Inherit Metab Dis 2013; 36 (02) 211-219
• 14 Mendelsohn NJ, Harmatz P, Bodamer O. , et al; Hunter Outcome Survey Investigators. Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey. Genet Med 2010; 12 (12) 816-822
• 15 Berger KI, Fagondes SC, Giugliani R. , et al. Respiratory and sleep disorders in mucopolysaccharidosis. J Inherit Metab Dis 2013; 36 (02) 201-210
• 16 Leboulanger N, Louis B, Vialle R, Heron B, Fauroux B. Analysis of the upper airway by the acoustic reflection method in children with mucopolysaccharidosis. Pediatr Pulmonol 2011; 46 (06) 587-594
• 17 Simmons MA, Bruce IA, Penney S, Wraith E, Rothera MP. Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 2005; 69 (05) 589-595
• 18 Morimoto N, Kitamura M, Kosuga M, Okuyama T. CT and endoscopic evaluation of larynx and trachea in mucopolysaccharidoses. Mol Genet Metab 2014; 112 (02) 154-159
• 19 Kamin W. Diagnosis and management of respiratory involvement in Hunter syndrome. Acta Paediatr 2008; 97 (457) 57-60
• 20 Malik V, Nichani J, Rothera MP. , et al. Tracheostomy in mucopolysaccharidosis type II (Hunter's syndrome). Int J Pediatr Otorhinolaryngol 2013; 77 (07) 1204-1208
• 21 Walker PP, Rose E, Williams JG. Upper airways abnormalities and tracheal problems in Morquio's disease. Thorax 2003; 58 (05) 458-459
• 22 Wippermann CF, Beck M, Schranz D, Huth R, Michel-Behnke I, Jüngst BK. Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr 1995; 154 (02) 98-101
• 23 Kimball TR. Pediatric stress echocardiography. Pediatr Cardiol 2002; 23 (03) 347-357
• 24 Hirth A, Berg A, Greve G. Successful treatment of severe heart failure in an infant with Hurler syndrome. J Inherit Metab Dis 2007; 30 (05) 820
• 25 Dilber E, Celiker A, Karagöz T, Kalkanoğlu HS. Permanent transfemoral pacemaker implantation in a child with Maroteaux Lamy syndrome. Pacing Clin Electrophysiol 2002; 25 (12) 1784-1785
• 26 Tandon V, Williamson JB, Cowie RA, Wraith JE. Spinal problems in mucopolysaccharidosis I (Hurler syndrome). J Bone Joint Surg Br 1996; 78 (06) 938-944
• 27 Thorne JA, Javadpour M, Hughes DG, Wraith E, Cowie RA. Craniovertebral abnormalities in type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome). Neurosurgery 2001; 48 (04) 849-852 , discussion 852–853
• 28 Kirkpatrick K, Ellwood J, Walker RW. Mucopolysaccharidosis type I (Hurler syndrome) and anesthesia: the impact of bone marrow transplantation, enzyme replacement therapy, and fiberoptic intubation on airway management. Paediatr Anaesth 2012; 22 (08) 745-751
• 29 Muenzer J, Wraith JE, Clarke LA. ; International Consensus Panel on Management and Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 2009; 123 (01) 19-29
• 30 de Ru MH, Boelens JJ, Das AM. , et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis 2011; 6: 55
• 31 Boelens JJ, Aldenhoven M, Purtill D. , et al; Eurocord; Inborn Errors Working Party of European Blood and Marrow Transplant group; Duke University Blood and Marrow Transplantation Program; Centre for International Blood and Marrow Research. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood 2013; 121 (19) 3981-3987
• 32 Aldenhoven M, Wynn RF, Orchard PJ. , et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood 2015; 125 (13) 2164-2172
• 33 Frawley G, Fuenzalida D, Donath S, Yaplito-Lee J, Peters H. A retrospective audit of anesthetic techniques and complications in children with mucopolysaccharidoses. Paediatr Anaesth 2012; 22 (08) 737-744
• 34 Muenzer J, Beck M, Giugliani R. , et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med 2011; 13 (02) 102-109
• 35 McGill JJ, Inwood AC, Coman DJ. , et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study. Clin Genet 2010; 77 (05) 492-498
• 36 Parini R, Deodato F, Di Rocco M. , et al. Open issues in mucopolysaccharidosis type I-Hurler. Orphanet J Rare Dis 2017; 12 (01) 112
• 37 Hack HA, Walker R, Gardiner P. Anaesthetic implications of the changing management of patients with mucopolysaccharidosis. Anaesth Intensive Care 2016; 44 (06) 660-668
• 38 Wraith JE, Beck M, Lane R. , et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 2007; 120 (01) e37-e46
• 39 Brands MM, Frohn-Mulder IM, Hagemans ML. , et al. Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI. J Inherit Metab Dis 2013; 36 (02) 227-234
• 40 Fesslová V, Corti P, Sersale G. , et al. The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young 2009; 19 (02) 170-178
• 41 Hendriksz CJ, Al-Jawad M, Berger KI. , et al. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis 2013; 36 (02) 309-322
• 42 Clarke LA, Wraith JE, Beck M. , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009; 123 (01) 229-240
• 43 Harmatz P, Whitley CB, Waber L. , et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004; 144 (05) 574-580
• 44 Harmatz P, Yu ZF, Giugliani R. , et al. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis 2010; 33 (01) 51-60
• 45 Pal AR, Langereis EJ, Saif MA. , et al. Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome. Orphanet J Rare Dis 2015; 10: 42
• 46 Burton BK, Jego V, Mikl J, Jones SA. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 2017; 40 (06) 867-874
• 47 Osthaus WA, Harendza T, Witt LH. , et al. Paediatric airway management in mucopolysaccharidosis 1: a retrospective case review. Eur J Anaesthesiol 2012; 29 (04) 204-207
• 48 Megens JH, de Wit M, van Hasselt PM, Boelens JJ, van der Werff DB, de Graaff JC. Perioperative complications in patients diagnosed with mucopolysaccharidosis and the impact of enzyme replacement therapy followed by hematopoietic stem cell transplantation at early age. Paediatr Anaesth 2014; 24 (05) 521-527
• 49 Theroux MC, Nerker T, Ditro C, Mackenzie WG. Anesthetic care and perioperative complications of children with Morquio syndrome. Paediatr Anaesth 2012; 22 (09) 901-907
• 50 Walker RW, Colovic V, Robinson DN, Dearlove OR. Postobstructive pulmonary oedema during anaesthesia in children with mucopolysaccharidoses. Paediatr Anaesth 2003; 13 (05) 441-447
• 51 Walker RW, Allen DL, Rothera MR. A fibreoptic intubation technique for children with mucopolysaccharidoses using the laryngeal mask airway. Paediatr Anaesth 1997; 7 (05) 421-426